{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:57:35Z","timestamp":1753891055887,"version":"3.41.2"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R38AI140297"],"award-info":[{"award-number":["R38AI140297"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Donor specific transfusions have been the basis of tolerance inducing protocols since Peter Medawar showed that it was experimentally feasible in the 1950s. Though trials of cellular therapies have become increasingly common in solid organ transplantation, they have not become standard practice. Additionally, whereas some protocols have focused on cellular therapies as a method for donor antigen delivery\u2014thought to promote tolerance in and of itself in the correct immunologic context\u2014other approaches have alternatively focused on the intrinsic immunosuppressive properties of the certain cell types with less emphasis on their origin, including mesenchymal stem cells, regulatory T cells, and regulatory dendritic cells. Regardless of intent, all cellular therapies must contend with the potential that introducing donor antigen in a new context will lead to sensitization. In this review, we focus on the variety of cellular therapies that have been applied in human trials and non-human primate models, describe their efficacy, highlight data regarding their potential for sensitization, and discuss opportunities for cellular therapies within our current understanding of the immune landscape.<\/jats:p>","DOI":"10.3389\/fimmu.2021.714723","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T18:01:15Z","timestamp":1630692075000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Cellular Therapies in Solid Organ Allotransplantation: Promise and Pitfalls"],"prefix":"10.3389","volume":"12","author":[{"given":"Brian I.","family":"Shaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Ord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Nobuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xunrong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/cjn.04800908","article-title":"Calcineurin Inhibitor Nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","article-title":"Tacrolimus versus Ciclosporin as Primary Immunosuppression for Kidney Transplant Recipients: Meta-Analysis and Meta-Regression of Randomised Trial Data","volume":"331","author":"Webster","year":"2005","journal-title":"Bmj"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03283.x","article-title":"Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal","volume":"11","author":"Lamb","year":"2011","journal-title":"Am J Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.05.018","article-title":"Analyses of the Short- And Long-Term Graft Survival after Kidney Transplantation in Europe between 1986 and 2015","volume":"94","author":"Coemans","year":"2018","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000002650","article-title":"No Gains in Long-term Survival After Liver Transplantation Over the Past Three Decades","volume":"269","author":"Rana","year":"2019","journal-title":"Ann Surg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/ajt.16502","article-title":"OPTN\/SRTR 2019 Annual Data Report: Kidney","volume":"21","author":"Hart","year":"2021","journal-title":"Am J Transplantation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/172603a0","article-title":"\u2018Actively Acquired Tolerance\u2019 of Foreign Cells","volume":"172","author":"Billingham","year":"1953","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.102.2651.400","article-title":"Immunogenetic Consequences Of Vascular Anastomoses Between Bovine Twins","volume":"102","author":"Owen","year":"1945","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00897","article-title":"Postnatal Involution and Counter-Involution of the Thymus","volume":"11","author":"Cowan","year":"2020","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.34067\/kid.0005692020","article-title":"Progress toward the Clinical Application of Mesenchymal Stromal Cells and Other Disease-Modulating Regenerative Therapies: Examples from the Field of Nephrology","volume":"2","author":"Hickson","year":"2021","journal-title":"Kidney360"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197811000-00001","article-title":"Blood Transfusion And Transplantation","volume":"26","author":"Van Rood","year":"1978","journal-title":"Transplantation"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-196407000-00001","article-title":"Increased Survival Of Renal Homografts In Dogs After Injection Of Graft Donor Blood","volume":"2","author":"Halasz","year":"1964","journal-title":"Transplantation"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197907000-00009","article-title":"Beneficial Effect Of Blood Transfusion: Role Of The Time Interval Between The Last Transfusion And Transplantation","volume":"28","author":"Hourmant","year":"1979","journal-title":"Transplantation"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)90608-6","article-title":"Beneficial Effect Of Operation-Day Blood-Transfusions On Human Renal-Allograft SURVIVAL","volume":"311","author":"Stiller","year":"1978","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-198010000-00012","article-title":"Deliberate Donor-Specific Blood Transfusions Prior To Living Related Renal Transplantation. A New Approach","volume":"192","author":"Salvatierra","year":"1980","journal-title":"Ann Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198012000-00007","article-title":"Effect of a Single Transfusion of Donor-Specific and Nonspecific Blood On Skin Allograft Survival in Mice","volume":"30","author":"Okazaki","year":"1980","journal-title":"Transplantation"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199001000-00006","article-title":"Living-Donor Renal Transplantation in SEOPF. The Impact of Histocompatibility, Transfusions, and Cyclosporine on Outcome","volume":"49","author":"Sanfilippo","year":"1990","journal-title":"Transplantation"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199110243251704","article-title":"Pretransplantation Blood Transfusion Revisited","volume":"325","author":"Twuyver","year":"1991","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.143.5.1447","article-title":"Tolerance Induction of Allo-Class II H-2 Antigen-Reactive L3T4+ Helper T Cells and Prolonged Survival of the Corresponding Class II H-2-Disparate Skin Graft","volume":"143","author":"Hori","year":"1989","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2009.01217.x","article-title":"CARI Donor-Specific Transfusions","volume":"15","author":"Mackie","year":"2010","journal-title":"Nephrology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.21.9560","article-title":"Survival of Mouse Pancreatic Islet Allografts in Recipients Treated With Allogeneic Small Lymphocytes and Antibody to CD40 Ligand","volume":"92","author":"Parker","year":"1995","journal-title":"Proc Natl Acad Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199712270-00003","article-title":"Donor Antigen Is Necessary for the Prevention of Chronic Rejection In CTLA4Ig-Treated Murine Cardiac Allograft Recipients","volume":"64","author":"Sayegh","year":"1997","journal-title":"Transplantation"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.24.13967","article-title":"Costimulatory Function and Expression of CD40 Ligand, CD80, and CD86 in Vascularized Murine Cardiac Allograft Rejection","volume":"93","author":"Hancock","year":"1996","journal-title":"Proc Natl Acad Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.1.512","article-title":"Treatment of Allograft Recipients With Donor-Specific Transfusion and anti-CD154 Antibody Leads to Deletion of Alloreactive CD8+ T Cells and Prolonged Graft Survival in a CTLA4-Dependent Manner","volume":"164","author":"Iwakoshi","year":"2000","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4049\/jimmunol.165.1.96","article-title":"Anti-TCR-Specific DNA Vaccination Demonstrates a Role for a CD8+ T Cell Clone in the Induction of Allograft Tolerance by Donor-Specific Blood Transfusion","volume":"165","author":"Vignes","year":"2000","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0586","article-title":"Mechanisms of Donor-Specific Transfusion Tolerance: Preemptive Induction of Clonal T-Cell Exhaustion via Indirect Presentation","volume":"102","author":"Quezada","year":"2003","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/01.Asn.0000137883.20961.2d","article-title":"Mechanism of Action of Donor-Specific Transfusion in Inducing Tolerance: Role of Donor MHC Molecules, Donor Co-Stimulatory Molecules, and Indirect Antigen Presentation","volume":"15","author":"Kishimoto","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.5.2776","article-title":"Studies Investigating Pretransplant Donor-Specific Blood Transfusion, Rapamycin, and the CD154-Specific Antibody IDEC-131 in a Nonhuman Primate Model of Skin Allotransplantation","volume":"170","author":"Xu","year":"2003","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00796.x","article-title":"IDEC-131 (Anti-CD154), Sirolimus and Donor-Specific Transfusion Facilitate Operational Tolerance in Non-Human Primates","volume":"5","author":"Preston","year":"2005","journal-title":"Am J Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000259929.04596.d5","article-title":"CD154 Blockade, Sirolimus, and Donor-Specific Transfusion Prevents Renal Allograft Rejection in Cynomolgus Monkeys Despite Homeostatic T-Cell Activation","volume":"83","author":"Pearl","year":"2007","journal-title":"Transplantation"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12712","article-title":"Renal Transplantation Using Belatacept Without Maintenance Steroids or Calcineurin Inhibitors","volume":"14","author":"Kirk","year":"2014","journal-title":"Am J Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16121","article-title":"Kidney Transplantation Using Alemtuzumab, Belatacept, and Sirolimus: Five-year Follow-Up","volume":"20","author":"Schmitz","year":"2020","journal-title":"Am J Transplantation"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00759.x","article-title":"Immunocompetent T-Cells With a Memory-Like Phenotype are the Dominant Cell Type Following Antibody-Mediated T-Cell Depletion","volume":"5","author":"Pearl","year":"2005","journal-title":"Am J Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(05)77739-4","article-title":"Prope Tolerance, Perioperative Campath 1H, and Low-Dose Cyclosporin Monotherapy in Renal Allograft Recipients","volume":"351","author":"Calne","year":"1998","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03543.x","article-title":"The risk and Opportunity of Homeostatic Repopulation","volume":"11","author":"Stock","year":"2011","journal-title":"Am J Transplant"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0805204105","article-title":"ECDI-Fixed Allogeneic Splenocytes Induce Donor-Specific Tolerance for Long-Term Survival of Islet Transplants via Two Distinct Mechanisms","volume":"105","author":"Luo","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04203.x","article-title":"Intragraft CD11b(+) IDO(+) Cells Mediate Cardiac Allograft Tolerance by ECDI-Fixed Donor Splenocyte Infusions","volume":"12","author":"Chen","year":"2012","journal-title":"Am J Transplant"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3727\/096368914x681027","article-title":"Preemptive Tolerogenic Delivery of Donor Antigens for Permanent Allogeneic Islet Graft Protection","volume":"24","author":"Wang","year":"2015","journal-title":"Cell Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302771","article-title":"Preemptive Donor Apoptotic Cell Infusions Induce IFN-\u03b3\u2013Producing Myeloid-Derived Suppressor Cells for Cardiac Allograft Protection","volume":"192","author":"Bryant","year":"2014","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3253","article-title":"Phagocytosis of Apoptotic Cells in Homeostasis","volume":"16","author":"Arandjelovic","year":"2015","journal-title":"Nat Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15087","article-title":"Receptor Tyrosine Kinase MerTK Suppresses an Allogenic Type I IFN Response to Promote Transplant Tolerance","volume":"19","author":"Zhang","year":"2019","journal-title":"Am J Transplantation"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1038\/s41467-019-11338-y","article-title":"Long-Term Tolerance of Islet Allografts in Nonhuman Primates Induced by Apoptotic Donor Leukocytes","volume":"10","author":"Singh","year":"2019","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15878","article-title":"Donor Apoptotic Cell-Based Therapy for Effective Inhibition of Donor-Specific Memory T and B Cells to Promote Long-Term Allograft Survival in Allosensitized Recipients","volume":"20","author":"Dangi","year":"2020","journal-title":"Am J Transplant"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000131165.37177.6e","article-title":"Generation of Tolerogenic Dendritic Cells by Treatment with Mitomycin C: Inhibition of Allogeneic T-Cell Response Is Mediated by Downregulation of ICAM-1, CD80, and CD86","volume":"77","author":"Jiga","year":"2004","journal-title":"Transplantation"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000248854.30016.11","article-title":"Inhibition of Heart Allograft Rejection with Mitomycin C-Treated Donor Dendritic Cells","volume":"83","author":"Jiga","year":"2007","journal-title":"Transplantation"},{"key":"B46","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1042\/cs20140258","article-title":"Generation of Suppressive Blood Cells for Control of Allograft Rejection","volume":"128","author":"Kleist","year":"2015","journal-title":"Clin Science"},{"key":"B47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00423-017-1616-3","article-title":"The Combination of Mitomycin-Induced Blood Cells with a Temporary Treatment of Ciclosporin A Prolongs Allograft Survival in Vascularized Composite Allotransplantation","volume":"403","author":"Radu","year":"2018","journal-title":"Langenbecks Arch Surg"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1172\/jci133595","article-title":"Phase I Trial of Donor-Derived Modified Immune Cell Infusion in Kidney Transplantation","volume":"130","author":"Morath","year":"2020","journal-title":"J Clin Invest"},{"key":"B49","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1084\/jem.169.2.493","article-title":"Mixed Chimerism and Permanent Specific Transplantation Tolerance Induced By a Nonlethal Preparative Regimen","volume":"169","author":"Sharabi","year":"1989","journal-title":"J Exp Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199501000-00018","article-title":"Mixed Allogeneic Chimerism and Renal Allograft Tolerance in Cynomolgus Monkeys","volume":"59","author":"Kawai","year":"1995","journal-title":"Transplantation"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199912150-00022","article-title":"Long-Term Outcome And Alloantibody Production In A Non-Myeloablative Regimen For Induction Of Renal Allograft Tolerance","volume":"68","author":"Kawai","year":"1999","journal-title":"Transplantation"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-Resolution Donor-Recipient HLA Matching Contributes to the Success of Unrelated Donor Marrow Transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199908270-00006","article-title":"Combined Histocompatibility Leukocyte Antigenmatched Donor Bone Marrow and Renal Transplantation for Multiple Myeloma with End Stage Renal Disease: The Induction of Allograft Tolerance through Mixed Lymphohematopoietic Chimerism","volume":"68","author":"Spitzer","year":"1999","journal-title":"Transplantation"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01434.x","article-title":"Myeloma Responses and Tolerance Following Combined Kidney and Nonmyeloablative Marrow Transplantation: In Vivo and In Vitro Analyses","volume":"6","author":"Fudaba","year":"2006","journal-title":"Am J Transplantation"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31820a3068","article-title":"Long-Term Follow-Up of Recipients of Combined Human Leukocyte Antigen-Matched Bone Marrow and Kidney Transplantation for Multiple Myeloma with End-Stage Renal Disease","volume":"91","author":"Spitzer","year":"2011","journal-title":"Transplantation"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071074","article-title":"HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression","volume":"358","author":"Kawai","year":"2008","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074191","article-title":"Tolerance and Chimerism after Renal and Hematopoietic-Cell Transplantation","volume":"358","author":"Scandling","year":"2008","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.03992.x","article-title":"Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants","volume":"12","author":"Scandling","year":"2012","journal-title":"Am J Transplantation"},{"key":"B59","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/ajt.13091","article-title":"Chimerism, Graft Survival, and Withdrawal of Immunosuppressive Drugs in HLA Matched and Mismatched Patients After Living Donor Kidney and Hematopoietic Cell Transplantation","volume":"15","author":"Scandling","year":"2015","journal-title":"Am J Transplantation"},{"key":"B60","doi-asserted-by":"publisher","first-page":"124ra28","DOI":"10.1126\/scitranslmed.3003509","article-title":"Chimerism and Tolerance without GVHD or Engraftment Syndrome in HLA-Mismatched Combined Kidney and Hematopoietic Stem Cell Transplantation","volume":"4","author":"Leventhal","year":"2012","journal-title":"Sci Trans Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/TP.0b013e3182782fc1","article-title":"Tolerance Induction in HLA Disparate Living Donor Kidney Transplantation by Donor Stem Cell Infusion: Durable Chimerism Predicts Outcome","volume":"95","author":"Leventhal","year":"2013","journal-title":"Transplantation"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2018.01.010","article-title":"Updated Follow-Up of a Tolerance Protocol in HLA-Identical Renal Transplant Pairs Given Donor Hematopoietic Stem Cells","volume":"79","author":"Leventhal","year":"2018","journal-title":"Hum Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A Phase III Study of Belatacept-Based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050085","article-title":"Costimulation Blockade with Belatacept in Renal Transplantation","volume":"353","author":"Vincenti","year":"2005","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and Long-Term Outcomes in Kidney Transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev.pathmechdis.3.121806.151508","article-title":"Kidney Transplantation: Mechanisms of Rejection and Acceptance","volume":"3","author":"Cornell","year":"2008","journal-title":"Annu Rev Pathol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/14653240600855905","article-title":"Minimal Criteria for Defining Multipotent Mesenchymal Stromal Cells. The International Society for Cellular Therapy Position Statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(08)60690-x","article-title":"Mesenchymal Stem Cells for Treatment of Steroid-Resistant, Severe, Acute Graft-Versus-Host Disease: A Phase II Study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2415","article-title":"Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFN\u03b3 Licensing","volume":"34","author":"Chinnadurai","year":"2016","journal-title":"Stem Cells"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(01)00769-X","article-title":"Mesenchymal Stem Cells Suppress Lymphocyte Proliferation in Vitro and Prolong Skin Graft Survival in Vivo","volume":"30","author":"Bartholomew","year":"2002","journal-title":"Exp Hematol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01191","article-title":"Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs. Review","volume":"10","author":"Weiss","year":"2019","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0586","article-title":"Human Mesenchymal Stem Cells Inhibit Differentiation and Function of Monocyte-Derived Dendritic Cells","volume":"105","author":"Jiang","year":"2005","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000244572.24780.54","article-title":"Mesenchymal Stem Cells Inhibit Dendritic Cell Differentiation and Function by Preventing Entry into the Cell Cycle","volume":"83","author":"Ramasamy","year":"2007","journal-title":"Transplantation"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep37566","article-title":"Umbilical Cord-Derived Mesenchymal Stem Cells Instruct Monocytes Towards an Il10-Producing Phenotype by Secreting IL6 and HGF","volume":"6","author":"Deng","year":"2016","journal-title":"Sci Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/stem.1432","article-title":"Multipotent Stromal Cells Induce Human Regulatory T Cells through a Novel Pathway Involving Skewing Of Monocytes toward Anti-Inflammatory Macrophages","volume":"31","author":"Melief","year":"2013","journal-title":"Stem Cells"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2009.08.072","article-title":"Bone Marrow\u2013Derived Mesenchymal Stem Cells Inhibit Acute Rejection of Rat Liver Allografts in Association with Regulatory T-Cell Expansion","volume":"41","author":"Wang","year":"2009","journal-title":"Transplant Proc"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02666","article-title":"Third-Party Allogeneic Mesenchymal Stromal Cells Prevent Rejection in a Pre-Sensitized High-Risk Model of Corneal Transplantation","volume":"41","author":"Lohan","year":"2009","journal-title":"Transplant Proc"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.6.3933","article-title":"Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells","volume":"181","author":"Casiraghi","year":"2008","journal-title":"J Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04115.x","article-title":"Localization of Mesenchymal Stromal Cells Dictates their Immune or Proinflammatory Effects in Kidney Transplantation","volume":"12","author":"Casiraghi","year":"2012","journal-title":"Am J Transplantation"},{"key":"B80","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3109\/14653240903253857","article-title":"Ex Vivo-Expanded Autologous Bone Marrow-Derived Mesenchymal Stromal Cells in Human Spinal Cord Injury\/Paraplegia: A Pilot Clinical Study","volume":"11","author":"Pal","year":"2009","journal-title":"Cytotherapy"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.02.001","article-title":"Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients","volume":"11","author":"Lazarus","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.04950610","article-title":"Autologous Mesenchymal Stromal Cells and Kidney Transplantation: A Pilot Study of Safety and Clinical Feasibility","volume":"6","author":"Perico","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.316","article-title":"Induction Therapy with Autologous Mesenchymal Stem Cells in Living-Related Kidney Transplants: A Randomized Controlled Trial","volume":"307","author":"Tan","year":"2012","journal-title":"JAMA"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2012-0114","article-title":"Autologous Bone Marrow-Derived Mesenchymal Stromal Cells for the Treatment of Allograft Rejection After Renal Transplantation: Results of a Phase I Study","volume":"2","author":"Reinders","year":"2013","journal-title":"Stem Cells Trans Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/nep.12338","article-title":"Safety and Efficacy of Autologous Mesenchymal Stromal Cells Transplantation in Patients Undergoing Living Donor Kidney Transplantation: A Pilot Study","volume":"20","author":"Mudrabettu","year":"2015","journal-title":"Nephrology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"12089","DOI":"10.18632\/oncotarget.7725","article-title":"Low-Dose Tacrolimus Combined with Donor-Derived Mesenchymal Stem Cells after Renal Transplantation: A Prospective, Non-Randomized Study","volume":"7","author":"Pan","year":"2016","journal-title":"Oncotarget"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-018-1422-x","article-title":"Allogeneic Mesenchymal Stem Cells as Induction Therapy Are Safe and Feasible In Renal Allografts: Pilot Results of a Multicenter Randomized Controlled Trial","volume":"16","author":"Sun","year":"2018","journal-title":"J Trans Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.kint.2018.08.046","article-title":"Infusion of Third-Party Mesenchymal Stromal Cells after Kidney Transplantation: A Phase I-II, Open-Label, Clinical Study","volume":"95","author":"Erpicum","year":"2019","journal-title":"Kidney Int"},{"key":"B89","doi-asserted-by":"publisher","first-page":"899","DOI":"10.5966\/sctm.2015-0002","article-title":"First-In-Human Case Study: Multipotent Adult Progenitor Cells for Immunomodulation after Liver Transplantation","volume":"4","author":"Soeder","year":"2015","journal-title":"Stem Cells Trans Med"},{"key":"B90","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jhep.2017.03.001","article-title":"Infusion of Mesenchymal Stromal Cells after Deceased Liver Transplantation: A Phase I\u2013Ii, Open-Label, Clinical Study","volume":"67","author":"Detry","year":"2017","journal-title":"J Hepatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.17-0198","article-title":"Feasibility, Safety, and Tolerance of Mesenchymal Stem Cell Therapy for Obstructive Chronic Lung Allograft Dysfunction","volume":"7","author":"Keller","year":"2018","journal-title":"Stem Cells Trans Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182754c53","article-title":"Donor-Derived Mesenchymal Stem Cells Combined With Low-Dose Tacrolimus Prevent Acute Rejection After Renal Transplantation: A Clinical Pilot Study","volume":"95","author":"Peng","year":"2013","journal-title":"Transplantation"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15910","article-title":"Human Leukocyte Antigen Selected Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplantation: The Neptune Study, A Phase I Single-Center Study","volume":"20","author":"Dreyer","year":"2020","journal-title":"Am J Transplantation"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1172\/JCI90594","article-title":"Danger Signals in Regulating the Immune Response to Solid Organ Transplantation","volume":"127","author":"Todd","year":"2017","journal-title":"J Clin Invest"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00243","article-title":"Editorial: Safety, Efficacy and Mechanisms of Action of Mesenchymal Stem Cell Therapies","volume":"11","author":"Moll","year":"2020","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01645","article-title":"Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application","volume":"10","author":"Caplan","year":"2019","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/stem.1111","article-title":"Are Therapeutic Human Mesenchymal Stromal Cells Compatible with Human Blood","volume":"30","author":"Moll","year":"2012","journal-title":"Stem Cells"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2018.12.006","article-title":"Intravascular Mesenchymal Stromal\/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines","volume":"25","author":"Moll","year":"2019","journal-title":"Trends Mol Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01091","article-title":"MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy","volume":"11","author":"Moll","year":"2020","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13287-021-02219-7","article-title":"Induction Therapy With Mesenchymal Stem Cells in Kidney Transplantation: A Meta-Analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30167-7","article-title":"Regulatory Cell Therapy in Kidney Transplantation (The ONE Study): A Harmonised Design and Analysis of Seven Non-Randomised, Single-Arm, Phase 1\/2A Trials","volume":"395","author":"Sawitzki","year":"2020","journal-title":"Lancet"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3734","article-title":"Regulatory T Cells for Minimising Immune Suppression in Kidney Transplantation: Phase I\/IIa Clinical Trial","volume":"371","author":"Roemhild","year":"2020","journal-title":"BMJ"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.714723\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T15:29:26Z","timestamp":1673191766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.714723\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":102,"alternative-id":["10.3389\/fimmu.2021.714723"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.714723","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"article-number":"714723"}}